Pill Identifier App

Data on Stapled Peptide Drugs to Be Presented at ASH Annual Meeting

Multiple Studies of Stapled Peptides, a new Drug Modality, Slated for Presentation at American Society of Hematology 2008 Meeting

CAMBRIDGE, MA - December 4, 2008 - Aileron Therapeutics announced today that investigators from Aileron and the Dana-Farber Cancer Institute will present data from multiple preclinical studies on stapled peptide drug candidates at the 50th Annual Meeting of the American Society of Hematology in San Francisco, Calif., December 6 to 9, 2008.

The schedule and meeting places for the sessions, together with the abstract information, are listed below:

"A Stapled p53 Helix Targets HDMX to Overcome Nutlin-3 Resistance and Reactivate the p53 Tumor Suppressor Pathway in Cancer" Sunday, December 7, 2008 at 6 p.m. Session Title: Molecular Pharmacology, Drug Resistance Abstract #2645; Poster Presentation (Poster Board II-739); Hall A Presenter: Federico Bernal, Ph.D., Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston, Harvard Medical School

"Structural Analysis of a BAX-BIM SAHB Complex Reveals a Novel BH3 Interaction Site on BAX for Therapeutic Activation of Apoptosis" Monday, December 8, 2008 at 8:45 a.m. Session Title: Tumor Suppressors and Oncogenes I Abstract #300; Location: 3002-3004 - West Presenter: Loren D. Walensky, M.D., Ph.D., Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston, Harvard Medical School

"Stapled Peptides: Leveraging the BH3 á-Helix to Create a New Class of Drugs to Treat Hematological Malignancies" Monday, December 8, 2008 at 5:30 p.m. Session Title: Acute Lymphocytic Leukemia - Therapy, Excluding Transplantation Abstract #2929; Poster Presentation (Poster Board III-11); Hall A Presenter: Rosana Kapeller, M.D., Ph.D., Vice President, Research, Aileron

"A Stapled BIM BH3 Helix Overcomes the MCL-1 Mediated Apoptotic Blockage of Refractory Hematologic Cancers" Tuesday, December 9, 2008 at 8:30 a.m. Session Title: New Targeted Drugs (pre-clinical) Abstract #862; Yerba Buena Ballroom Salon 8 (San Francisco Marriott) Presenter: James L. LaBelle, M.D., Ph.D., Pediatric Oncology and the Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Children's Hospital Boston, Harvard Medical School

About Stapled Peptides AILERON's Stapled Peptides are synthetically locked, or 'stapled', into an alpha-helical shape with an optimized cross-linking chemistry to mimic the structure found at the interface of many protein-protein interactions. To achieve this, Aileron has deployed a comprehensive cross-linking tool-kit to install single staples, multiple staples and contiguous staples to achieve desired efficacy and pharmacokinetic profiles. The resulting Stapled Peptide drugs are endowed with unique properties, including efficient cell penetration, high affinity binding to large target protein surfaces, and excellent stability and pharmacokinetic properties within the body.

About Aileron Therapeutics Aileron Therapeutics is a biopharmaceutical company leading the development of a completely new therapeutic modality and class of drugs called Stapled Peptides, and with deep and broad knowledge and experience around this new technology. Stapled Peptide drugs represent the first solution for modulating intracellular protein-protein interactions, which have been identified as critical control points for most human diseases. As such, Stapled Peptide drugs offer a unique opportunity to exploit potentially thousands of currently "undruggable" targets across all human diseases. Aileron is building a robust pipeline of therapeutics for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases. Aileron Therapeutics was founded in 2005 and is based in Cambridge, Massachusetts. For additional information, please visit http://www.aileronrx.com.

 

 

 

Posted: December 2008

View comments

Hide
(web2)